|
|||
|
Time Date
To access many of the downloads on this website you will need Adobe Acrobat Reader. This can be obtained free by clicking here or by clicking the image below: .
Crohn's and Colitis UK is the working name for The National
Association for Colitis and Crohn's Disease (NACC)
Website
last updated:
|
Please note: The following article has been included at the request of staff based at the Hallamshire Hospital - it may be that other hospitals in the South Yorkshire region are taking part in this research Comparison of infliximab and ciclosporinin steroid resistant ulcerative colitis: a trial (CONSTRUCT) CONSTRUCT is a UK-wide clinical trial of two powerful treatments for acute severe ulcerative colitis that is unresponsive to intravenous steroids. At least 40 hospitals will take part inthe trial and 14 of them are now actively recruiting. At the time of writing 22 patients have been admitted and treated with steroids for severe colitis. Two of these patients have failed to respond to steroids and have been randomised to either infliximab or ciclosporin. This is a very important trial as it will tell us which of the drugs is more cost effective and also give us information on the long term outcome following treatment. A review of current evidence, commissioned by NICE in 2008, specifically called for this comparison to enable them to make a decision as to which drug to recommend. It is clear that both treatments delay surgery but infliximab is about 10 times more expensive than ciclosporin and we do not yet know whether the short and long term effectiveness justifies this additional cost. If you are unfortunate enough to be admitted with acute severe ulcerative colitis please ask if the trial is active in your area. If you are asked to take part you will be given detailed information about the study and asked to sign a consent form before being allocated one of the two treatments, at random. Taking part will help us build the evidence about these two drugs in this situation, and will hopefully contribute to the better care of other patients in the future as we learn moreabout the short and long term benefits. It is likely that taking part will also give you greater insight into your condition and understanding of the way we conduct research. This is the only study looking at these particular issues. There is a short term study in progress in France but it will not tell us the long term outcome nor a comparison of costs, so there will be benefits to both yourself, and to many others, from taking part. Please ask your consultant if the trial is active in your area, and spread the word if it is! Further information can be obtained from the CONSTRUCT team, who can be emailed at construct@swansea.ac.uk. Article posted: 01/11/11 |
||
|
|||
Home
